421,700 Shares in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Purchased by Voss Capital LP

Voss Capital LP acquired a new position in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund acquired 421,700 shares of the biotechnology company's stock, valued at approximately $5,301,000. Voss Capital LP owned approximately 0.46% of Rocket Pharmaceuticals as of its most recent filing with the SEC.

Several other institutional investors have also modified their holdings of the company. Covestor Ltd lifted its holdings in shares of Rocket Pharmaceuticals by 33,166.7% during the fourth quarter. Covestor Ltd now owns 1,996 shares of the biotechnology company's stock valued at $25,000 after purchasing an additional 1,990 shares during the last quarter. Signaturefd LLC boosted its stake in Rocket Pharmaceuticals by 319.8% in the 4th quarter. Signaturefd LLC now owns 4,916 shares of the biotechnology company's stock worth $62,000 after purchasing an additional 3,745 shares during the period. Harbour Investments Inc. grew its position in Rocket Pharmaceuticals by 51.9% during the 4th quarter. Harbour Investments Inc. now owns 5,385 shares of the biotechnology company's stock worth $68,000 after purchasing an additional 1,840 shares in the last quarter. KBC Group NV raised its stake in Rocket Pharmaceuticals by 159.6% during the 4th quarter. KBC Group NV now owns 5,475 shares of the biotechnology company's stock valued at $69,000 after purchasing an additional 3,366 shares during the period. Finally, E Fund Management Co. Ltd. purchased a new stake in shares of Rocket Pharmaceuticals in the fourth quarter valued at $139,000. Institutional investors and hedge funds own 98.39% of the company's stock.

Analyst Ratings Changes

Several research firms recently weighed in on RCKT. Needham & Company LLC reissued a "buy" rating and set a $42.00 price target on shares of Rocket Pharmaceuticals in a research report on Wednesday, April 9th. Scotiabank increased their price target on shares of Rocket Pharmaceuticals from $51.00 to $52.00 and gave the stock a "sector outperform" rating in a research report on Monday, March 3rd. Chardan Capital lowered their price objective on shares of Rocket Pharmaceuticals from $62.00 to $54.00 and set a "buy" rating on the stock in a research report on Friday, February 28th. Canaccord Genuity Group dropped their price objective on shares of Rocket Pharmaceuticals from $39.00 to $36.00 and set a "buy" rating on the stock in a research note on Monday, March 3rd. Finally, The Goldman Sachs Group decreased their target price on shares of Rocket Pharmaceuticals from $29.00 to $15.00 and set a "neutral" rating for the company in a research note on Monday, March 3rd. One investment analyst has rated the stock with a hold rating and eleven have given a buy rating to the stock. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus price target of $43.00.

Insider Activity at Rocket Pharmaceuticals

In other news, CEO Gaurav Shah purchased 20,000 shares of the stock in a transaction that occurred on Thursday, April 10th. The shares were purchased at an average cost of $5.08 per share, for a total transaction of $101,600.00. Following the completion of the purchase, the chief executive officer now directly owns 792,680 shares of the company's stock, valued at approximately $4,026,814.40. The trade was a 2.59 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Aaron Ondrey sold 7,489 shares of the company's stock in a transaction that occurred on Friday, April 4th. The shares were sold at an average price of $5.29, for a total value of $39,616.81. Following the completion of the transaction, the chief financial officer now directly owns 129,650 shares of the company's stock, valued at approximately $685,848.50. This trade represents a 5.46 % decrease in their position. The disclosure for this sale can be found here. 28.50% of the stock is owned by corporate insiders.

Rocket Pharmaceuticals Stock Performance

Shares of Rocket Pharmaceuticals stock traded down $0.20 on Friday, reaching $7.23. The stock had a trading volume of 1,634,069 shares, compared to its average volume of 1,326,622. The company has a debt-to-equity ratio of 0.06, a quick ratio of 6.05 and a current ratio of 6.05. The business's 50-day moving average price is $7.64 and its two-hundred day moving average price is $11.40. The stock has a market cap of $770.93 million, a P/E ratio of -2.63 and a beta of 1.00. Rocket Pharmaceuticals, Inc. has a fifty-two week low of $4.55 and a fifty-two week high of $26.98.

Rocket Pharmaceuticals (NASDAQ:RCKT - Get Free Report) last released its earnings results on Monday, March 3rd. The biotechnology company reported ($0.62) earnings per share for the quarter, topping analysts' consensus estimates of ($0.68) by $0.06. On average, sell-side analysts forecast that Rocket Pharmaceuticals, Inc. will post -2.83 EPS for the current year.

About Rocket Pharmaceuticals

Rocket Pharmaceuticals, Inc, together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia.